Anidulafungin pharmacokinetics in critically ill patients
MJP van Wanrooy, MMG Rodgers, DRA Uges, JP Arends, JG Zijlstra, TS van der Werf, JGW Kosterink, JWC Alffenaar*
*Corresponding author: JWC Alffenaar
Department of Hospital and Clinical Pharmacy, University Medical Center Groningen, Groningen, Netherlands
F1000 Posters 2012, 3: 318 (poster) [English] Poster [206.96 KB]
Presented at
22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2012, 31 Mar – 3 Apr 2012,
Background / Purpose:
Early antifungal treatment with adequate drug exposure reduces mortality in patients with candidemia. Efficacy of anidulafungin is driven by the AUC (area under the curve)/MIC ratio. As anidulafungin clearance is approximately 30% higher in patients with invasive candidiasis than in patients with oesophageal candidiasis, patients at the ICU may be at risk of underexposure. Therefore, insight in anidulafungin pharmacokinetics in a ‘real-life’ population of critically ill patients is important.
Early antifungal treatment with adequate drug exposure reduces mortality in patients with candidemia. Efficacy of anidulafungin is driven by the AUC (area under the curve)/MIC ratio. As anidulafungin clearance is approximately 30% higher in patients with invasive candidiasis than in patients with oesophageal candidiasis, patients at the ICU may be at risk of underexposure. Therefore, insight in anidulafungin pharmacokinetics in a ‘real-life’ population of critically ill patients is important.
Please note that most posters on this site present work that is preliminary in nature and has not been peer reviewed.
This poster is open access subject to the Non-Commercial Creative Commons 3.0 License
Poster F1000
